NSE ScannerComparison · NSE · data 2026-11-01
Infinium Pharmachem Ltd. vs Medicamen Biotech Limited
In plain words
Size: Infinium Pharmachem Ltd. is about 1.3 times the market value of Medicamen Biotech Limited.
Valuation (P/E): Infinium Pharmachem Ltd. 36 vs Medicamen Biotech Limited 31.3.
Return on equity: Infinium Pharmachem Ltd. 10.5% vs Medicamen Biotech Limited 3.9%.
Profit growth over 3 years: Infinium Pharmachem Ltd. 8.6% a year vs Medicamen Biotech Limited -13.4% a year.
Differences in the numbers, not a recommendation of either stock.
Side by side
| INFINIUM | MEDICAMEQ | |
|---|---|---|
| Price | ₹281 | ₹256.2 |
| Market cap | ₹438 cr | ₹347 cr |
| P/E | 36 | 31.3 |
| P/B | 3.6 | — |
| ROE | 10.5% | 3.9% |
| ROCE | 13.5% | 5.5% |
| Debt / equity | 0.19 | 0.18 |
| Operating margin | 9.8% | 6.0% |
| Dividend yield | 0.00% | 0.39% |
| Sales growth, 3 years (yearly) | 18.4% | 12.0% |
| Profit growth, 3 years (yearly) | 8.6% | -13.4% |
| 1-year return | 8.0% | -27.6% |
| Revenue, last 12 months | ₹190 cr | ₹203 cr |
| Net profit, last 12 months | ₹12 cr | ₹11 cr |
| Latest quarter | — | Jun 2026 |
| Quarter net profit | — | ₹2 cr |
| Quarter profit vs a year earlier | — | -1.4% |
| Promoter holding | — | 40.46% |
| Health check | Strong (6.9/10) | Average (4.2/10) |
Common questions
Which has a higher P/E, Infinium Pharmachem Ltd. or Medicamen Biotech Limited?
Infinium Pharmachem Ltd. trades at the higher P/E (36 against 31.3). A higher P/E means the market pays more for each rupee of past earnings; on its own it does not say which is better.
Which earns a higher return on equity?
Infinium Pharmachem Ltd. (10.5% against 3.9%).
Which carries more debt?
Infinium Pharmachem Ltd. has the higher debt-to-equity ratio (0.19 against 0.18).